(Q38752466)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26921096%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

title

Mutation distributions and clinical correlations of PIK3CA gene mutations in breast cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26921096%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26921096%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

author name string

Ebubekir Dirican

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26921096%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

Ayşe Özer

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26921096%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

publication date

26 February 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26921096%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26921096%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

volume

37

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26921096%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26921096%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

page(s)

7033-7045

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26921096%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s13277-016-4924-2

9 March 2020

exact match

0 references

cites work

Adipocyte activation of cancer stem cell signaling in breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4924-2

The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4924-2

21 January 2018

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4924-2

21 January 2018

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4924-2

Tumour heterogeneity in the clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4924-2

Cell proliferation in carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4924-2

Role of estrogen receptor signaling in breast cancer metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4924-2

Association of phosphatidylinositol kinase activity with polyoma middle-T competent for transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4924-2

Evidence that the Rous sarcoma virus transforming gene product phosphorylates phosphatidylinositol and diacylglycerol

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4924-2

Signaling by the phosphoinositide 3-kinase family in immune cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4924-2

Mutation of the PIK3CA oncogene in human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4924-2

PIK3CA mutations in human solid tumors: role in sensitivity to various therapeutic approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4924-2

High frequency of mutations of the PIK3CA gene in human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4924-2

Targeting the phosphoinositide 3-kinase pathway in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4924-2

Targeting PI3K signalling in cancer: opportunities, challenges and limitations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4924-2

The emerging mechanisms of isoform-specific PI3K signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4924-2

PI3K class IB pathway in neutrophils

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4924-2

Oncogenic PI3K deregulates transcription and translation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4924-2

PIK3CA gene mutations in pediatric and adult glioblastoma multiforme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4924-2

New phosphatidylinositol 3-kinase inhibitors for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4924-2

High-throughput interrogation of PIK3CA, PTEN, KRAS, FBXW7 and TP53 mutations in primary endometrial carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4924-2

Genetically engineered mouse models of PI3K signaling in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4924-2

Frequent mutation of the PIK3CA gene in ovarian and breast cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4924-2

PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4924-2

Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4924-2

PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4924-2

An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4924-2

Ligand-dependent interaction of estrogen receptor-alpha with members of the forkhead transcription factor family

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4924-2

Down-regulation of phosphatidylinositol 3'-kinase/AKT/molecular target of rapamycin metabolic pathway by primary letrozole-based therapy in human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4924-2

Glucose-potentiated chemotaxis in human vascular smooth muscle is dependent on cross-talk between the PI3K and MAPK signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4924-2

PIK3CA mutation associates with improved outcome in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4924-2

PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4924-2

Ras Signaling Is a Key Determinant for Metastatic Dissemination and Poor Survival of Luminal Breast Cancer Patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4924-2

PIK3CA Mutations are Common in Many Tumor Types and are Often Associated With Other Driver Mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4924-2

Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4924-2

PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4924-2

PI3K pathway activation in high-grade ductal carcinoma in situ--implications for progression to invasive breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4924-2

Analysis of PIK3CA mutations in breast cancer subtypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4924-2

Oncogenic PIK3CA mutations in lobular breast cancer progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4924-2

Dual Blockade with AFatinib and Trastuzumab as NEoadjuvant Treatment for Patients with Locally Advanced or Operable Breast Cancer Receiving Taxane-Anthracycline Containing Chemotherapy-DAFNE (GBG-70).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4924-2

HER (erbB) tyrosine kinase inhibitors in the treatment of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4924-2

Epidermal growth factor receptor tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4924-2

Combination of imatinib and clotrimazole enhances cell growth inhibition in T47D breast cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4924-2

PIK3CA mutations in breast cancer: reconciling findings from preclinical and clinical data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4924-2

Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K/mTOR inhibitor, in combination with sorafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4924-2

Effects of PI3K inhibitor NVP-BKM120 on overcoming drug resistance and eliminating cancer stem cells in human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4924-2

Phase I/II dose-escalation study of PI3K inhibitors pilaralisib or voxtalisib in combination with letrozole in patients with hormone-receptor-positive and HER2-negative metastatic breast cancer refractory to a non-steroidal aromatase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4924-2

Dual treatments targeting IGF-1R, PI3K, mTORC or MEK synergize to inhibit cell growth, induce apoptosis, and arrest cell cycle at G1 phase in MDA-MB-231 cell line.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4924-2

Synergistic anticancer efficacy of MEK inhibition and dual PI3K/mTOR inhibition in castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4924-2

mTOR inhibitors counteract tamoxifen-induced activation of breast cancer stem cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4924-2

Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4924-2

PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4924-2

Management of breast cancer with targeted agents: importance of heterogeneity. [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4924-2

PIK3CA Pathway Mutations Predictive of Poor Response Following Standard Radiochemotherapy ± Cetuximab in Cervical Cancer Patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4924-2

Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: efficacy, safety, and biomarker results from Japanese patients phase II studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4924-2

PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4924-2

PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4924-2

Targeting EGFR and PI3K pathways in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4924-2

PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4924-2

Rapid detection of genetic mutations in individual breast cancer patients by next-generation DNA sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4924-2

Measurement of PIP3 levels reveals an unexpected role for p110β in early adaptive responses to p110α-specific inhibitors in luminal breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4924-2

Phase I/II study of pilaralisib (SAR245408) in combination with trastuzumab or trastuzumab plus paclitaxel in trastuzumab-refractory HER2-positive metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4924-2

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4924-2

Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4924-2

Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4924-2

Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4924-2

The PI3K pathway as drug target in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4924-2

Carcinogenesis of PIK3CA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4924-2

Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4924-2

PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4924-2

PIK3CA mutations in serum DNA are predictive of recurrence in primary breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4924-2

Comprehensive DNA Methylation and Extensive Mutation Analyses of HER2-Positive Breast Cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4924-2

Significance of PIK3CA Mutations in Patients with Early Breast Cancer Treated with Adjuvant Chemotherapy: A Hellenic Cooperative Oncology Group (HeCOG) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4924-2

Next generation sequencing of triple negative breast cancer to find predictors for chemotherapy response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4924-2

Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4924-2

Comparison of cell stabilizing blood collection tubes for circulating plasma tumor DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4924-2

Predictive Biomarker Profiling of > 6000 Breast Cancer Patients Shows Heterogeneity in TNBC, With Treatment Implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4924-2

An integrative analysis of PIK3CA mutation, PTEN, and INPP4B expression in terms of trastuzumab efficacy in HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4924-2

Heterogeneity of PIK3CA mutational status at the single cell level in circulating tumor cells from metastatic breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4924-2

Mutational profiling of familial male breast cancers reveals similarities with luminal A female breast cancer with rare TP53 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4924-2

PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4924-2

Changes in PIK3CA mutation status are not associated with recurrence, metastatic disease or progression in endocrine-treated breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4924-2

Mutational analysis of PI3K/AKT signaling pathway in tamoxifen exemestane adjuvant multinational pathology study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4924-2

PIK3CA mutations are a predictor of docetaxel plus epirubicin neoadjuvant chemotherapy clinical efficacy in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4924-2

Relationship of PIK3CA mutation and pathway activity with antiproliferative response to aromatase inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4924-2

PIK3CA mutations in Peruvian patients with HER2-amplified and triple negative non-metastatic breast cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4924-2

Activated PI3K/AKT and MAPK pathways are potential good prognostic markers in node-positive, triple-negative breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4924-2

Frequent PIK3CA mutations in radial scars

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4924-2

Multiplex detection of DNA mutations by the fluorescence fingerprint spectrum technique

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4924-2

Preemptive tumor profiling for biomarker-stratified early clinical drug development in metastatic breast cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4924-2

Expression of PIK3CA, PTEN mRNA and PIK3CA mutations in primary breast cancer: association with lymph node metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4924-2

Frequent genetic alterations in EGFR- and HER2-driven pathways in breast cancer brain metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4924-2

Prevalence of PIK3CA mutations and the SNP rs17849079 in Arab breast cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4924-2

PIK3CA mutations are frequently observed in BRCAX but not BRCA2-associated male breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4924-2

Analysing the mutational status of PIK3CA in circulating tumor cells from metastatic breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4924-2

Somatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4924-2

Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4924-2

Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4924-2

Novel method for PIK3CA mutation analysis: locked nucleic acid--PCR sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4924-2

PIK3CA-AKT pathway mutations in micropapillary breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4924-2

Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4924-2

PIK3CA exon 20 mutations are associated with poor prognosis in breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4924-2

Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4924-2

Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4924-2

Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4924-2

PIK3CA mutation impact on survival in breast cancer patients and in ERα, PR and ERBB2-based subgroups

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4924-2

PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4924-2

PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4924-2

Phosphatidylinositol 3-kinase (PI3KCA) oncogene mutation analysis and gene expression profiling in primary breast cancer patients

21 January 2018

1 reference

12 December 2020

The origins of human cancer: molecular mechanisms of carcinogenesis and their implications for cancer prevention and treatment--twenty-seventh G.H.A. Clowes memorial award lecture.

1 reference

12 December 2020

Mutational analysis of key EGFR pathway genes in Chinese breast cancer patients

1 reference

12 December 2020

Imatinib: A Viewpoint by Brian J. Druker

1 reference

12 December 2020

Compound HRAS/PIK3CA mutations in Chinese patients with alveolar rhabdomyosarcomas

1 reference

12 December 2020

Phospho-PRAS40(Thr246) predicts trastuzumab response in patients with HER2-positive metastatic breast cancer

1 reference

12 December 2020

Effects of oncogenic p110alpha subunit mutations on the lipid kinase activity of phosphoinositide 3-kinase

1 reference

12 December 2020

Racial differences in breast cancer patterns

1 reference

12 December 2020

PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer

1 reference

12 December 2020

Rare PIK3CA hotspot mutations in carcinomas of the biliary tract

1 reference

12 December 2020

Evaluation of PTEN loss and PIK3CA mutations and their correlation with efficacy of trastuzumab treatment in HER2-positive metastatic breast cancer: A retrospective study (KBC-SG 1001)

1 reference

12 December 2020

Oncogenes, antioncogenes, and the molecular bases of multistep carcinogenesis

1 reference

12 December 2020

The phosphatidylinositol 3'-kinase p85alpha gene is an oncogene in human ovarian and colon tumors.

1 reference

12 December 2020

Oncogenic mutations of the PIK3CA gene in head and neck squamous cell carcinomas

1 reference

12 December 2020

Prognostic value of PIK3CA mutation status, PTEN and androgen receptor expression for metastasis-free survival in HER2-positive breast cancer patients treated with trastuzumab in adjuvant setting

1 reference

12 December 2020

Favorable prognostic impact in loss of TP53 and PIK3CA mutations after neoadjuvant chemotherapy in breast cancer

1 reference

12 December 2020

Analysis of PIK3CA exon 9 and 20 mutations in breast cancers using PCR-HRM and PCR-ARMS: correlation with clinicopathological criteria.

1 reference

12 December 2020

Correlation between activation of PI3K/AKT/mTOR pathway and prognosis of breast cancer in Chinese women

1 reference

12 December 2020

PIK3CA and TP53 gene mutations in human breast cancer tumors frequently detected by ion torrent DNA sequencing

1 reference

12 December 2020

The docking molecule gab2 is induced by lymphocyte activation and is involved in signaling by interleukin-2 and interleukin-15 but not other common gamma chain-using cytokines

1 reference

12 December 2020

Activation of phosphatidylinositol 3-kinase-protein kinase B (PI3K-PKB) induced by 17beta-estradiol in endometrial carcinoma cell (Ishikawa)

1 reference

12 December 2020

Genetic alterations in the PI3K pathway in prostate cancer.

1 reference

12 December 2020

[Correlation between the incidence of PIK3CA mutations in breast cancer and histopathological characteristics of the tumor].

1 reference

12 December 2020

Detection of PIK3CA gene mutations with HRM analysis and association with IGFBP-5 expression levels in breast cancer.

1 reference

12 December 2020

Deciphering the impact of somatic mutations in exon 20 and exon 9 of PIK3CA gene in breast tumors among Indian women through molecular dynamics approach.

1 reference

12 December 2020

Clinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese women

1 reference

12 December 2020

10.1007/S13277-016-4924-2

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26921096%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

9 March 2020

1017033802

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26921096%20AND%20SRC:MED&resulttype=core&format=json